Cerebrospinal fluid alpha-synuclein as a biomarker for Parkinson's disease diagnosis: a systematic review and meta-analysis

References

• de Lau LM, Breteler MM. Epidemiology of Parkinson's disease. Lancet Neurol 2006;5:525–35.
   PubMed Web of Science ®Google Scholar
• Marti MJ, Tolosa E, Campdelacreu J. Clinical overview of the synucleinopathies. Mov Disord 2003;18(Suppl 6):S21–7.
   PubMed Web of Science ®Google Scholar
• Shi M, Bradner J, Hancock AM, et al. Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression. Ann Neurol 2011;69:570–80.
   PubMed Web of Science ®Google Scholar
• Lang AE, Lozano AM. Parkinson's disease. First of two parts. N Engl J Med 1998;339:1044–53.
   PubMed Web of Science ®Google Scholar
• Lang AE, Lozano AM. Parkinson's disease. Second of two parts. N Engl J Med 1998;339:1130–43.
   PubMed Web of Science ®Google Scholar
• Hughes AJ, Daniel SE, Blankson S, Lees AJ. A clinicopathologic study of 100 cases of Parkinson's disease. Arch Neurol 1993;50:140–8.
   PubMed Web of Science ®Google Scholar
• van Dijk KD, Bidinosti M, Weiss A, et al. Reduced alpha-synuclein levels in cerebrospinal fluid in Parkinson's disease are unrelated to clinical and imaging measures of disease severity. Eur J Neurol 2013;21:388–94.
   PubMed Web of Science ®Google Scholar
• Mollenhauer B, Cullen V, Kahn I, et al. Direct quantification of CSF alpha-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration. Exp Neurol 2008;213:315–25.
   PubMed Web of Science ®Google Scholar
• Hong Z, Shi M, Chung KA, et al. DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease. Brain 2010;133:713–26.
   PubMed Web of Science ®Google Scholar
• Mollenhauer B, Locascio JJ, Schulz-Schaeffer W, et al. alpha-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study. Lancet Neurol 2011;10:230–40.
   PubMed Web of Science ®Google Scholar
• Hall S, Ohrfelt A, Constantinescu R, et al. Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders. Arch Neurol 2012;69:1445–52.
   PubMed Web of Science ®Google Scholar
• Mollenhauer B, Trautmann E, Taylor P, et al. Total CSF alpha-synuclein is lower in de novo Parkinson patients than in healthy subjects. Neurosci Lett 2013;532:44–8.
   PubMed Web of Science ®Google Scholar
• Toledo JB, Korff A, Shaw LM, et al. CSF alpha-synuclein improves diagnostic and prognostic performance of CSF tau and Abeta in Alzheimer's disease. Acta Neuropathol 2013;126:683–97.
   PubMed Web of Science ®Google Scholar
• Wennstrom M, Surova Y, Hall S, et al. Low CSF levels of both alpha-synuclein and the alpha-synuclein cleaving enzyme neurosin in patients with synucleinopathy. PLoS One 2013;8:e53250.
   PubMed Web of Science ®Google Scholar
• Ohrfelt A, Grognet P, Andreasen N, et al. Cerebrospinal fluid alpha-synuclein in neurodegenerative disorders-a marker of synapse loss? Neurosci Lett 2009;450:332–5.
   PubMed Web of Science ®Google Scholar
• Reesink FE, Lemstra AW, van Dijk KD, et al. CSF alpha-synuclein does not discriminate dementia with Lewy bodies from Alzheimer's disease. J Alzheimers Dis 2010;22:87–95.
   PubMed Web of Science ®Google Scholar
• Park MJ, Cheon SM, Bae HR, et al. Elevated levels of alpha-synuclein oligomer in the cerebrospinal fluid of drug-naive patients with Parkinson's disease. J Clin Neurol 2011;7:215–22.
   PubMed Web of Science ®Google Scholar
• Aerts MB, Esselink RA, Abdo WF, et al. CSF alpha-synuclein does not differentiate between parkinsonian disorders. Neurobiol Aging 2012;33(430):e431–33.
   Google Scholar
• Tateno F, Sakakibara R, Kawai T, et al. Alpha-synuclein in the cerebrospinal fluid differentiates synucleinopathies (Parkinson Disease, dementia with Lewy bodies, multiple system atrophy) from Alzheimer disease. Alzheimer Dis Assoc Disord 2012;26:213–6.
   PubMed Web of Science ®Google Scholar
• Parnetti L, Chiasserini D, Bellomo G, et al. Cerebrospinal fluid Tau/alpha-synuclein ratio in Parkinson's disease and degenerative dementias. Mov Disord 2011;26:1428–35.
   PubMed Web of Science ®Google Scholar
• Gibb WR. Accuracy in the clinical diagnosis of parkinsonian syndromes. Postgrad Med J 1988;64:345–51.
   PubMed Web of Science ®Google Scholar
• Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181–4.
   PubMed Web of Science ®Google Scholar
• McKeith IG, Dickson DW, Lowe J, et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 2005;65:1863–72.
   PubMed Web of Science ®Google Scholar
• Gilman S, Wenning GK, Low PA, et al. Second consensus statement on the diagnosis of multiple system atrophy. Neurology 2008;71:670–6.
   PubMed Web of Science ®Google Scholar
• McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939–44.
   PubMed Web of Science ®Google Scholar
• Whiting PF, Rutjes AW, Westwood ME, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med 2011;155:529–36.
   PubMed Web of Science ®Google Scholar
• Mollenhauer B, El-Agnaf OM, Marcus K, et al. Quantification of alpha-synuclein in cerebrospinal fluid as a biomarker candidate: review of the literature and considerations for future studies. Biomark Med 2010;4:683–99.
   PubMed Web of Science ®Google Scholar
• Eller M, Williams DR. Biological fluid biomarkers in neurodegenerative parkinsonism. Nat Rev Neurol 2009;5:561–70.
   PubMed Web of Science ®Google Scholar
• Beyer K. Alpha-synuclein structure, posttranslational modification and alternative splicing as aggregation enhancers. Acta Neuropathol 2006;112:237–51.
   PubMed Web of Science ®Google Scholar
• Wang Y, Shi M, Chung KA, et al. Phosphorylated alpha-synuclein in Parkinson's disease. Sci Transl Med 2012;4: 121ra120.
   Web of Science ®Google Scholar
• Tokuda T, Qureshi MM, Ardah MT, et al. Detection of elevated levels of alpha-synuclein oligomers in CSF from patients with Parkinson disease. Neurology 2010;75:1766–72.
   PubMed Web of Science ®Google Scholar
• Bruggink KA, Kuiperij HB, Ekholm-Pettersson F, Verbeek MM. Detection of elevated levels of alpha-synuclein oligomers in CSF from patients with Parkinson disease. Neurology 2011;77:510–1.
   PubMed Web of Science ®Google Scholar
• Sierks MR, Chatterjee G, McGraw C, et al. CSF levels of oligomeric alpha-synuclein and beta-amyloid as biomarkers for neurodegenerative disease. Integr Biol (Camb) 2011;3:1188–96.
   PubMed Web of Science ®Google Scholar
• Tokuda T, Salem SA, Allsop D, et al. Decreased alpha-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson's disease. Biochem Biophys Res Commun 2006;349:162–6.
   PubMed Web of Science ®Google Scholar
• Kang JH, Irwin DJ, Chen-Plotkin AS, et al. Association of cerebrospinal fluid beta-amyloid 1-42, T-tau, P-tau181, and alpha-synuclein levels with clinical features of drug-naive patients with early Parkinson disease. JAMA Neurol 2013;70:1277–87.
   PubMed Web of Science ®Google Scholar
• Morley JF, Duda JE. Olfaction as a biomarker in Parkinson's disease. Biomark Med 2010;4:661–70.
   PubMed Web of Science ®Google Scholar
• Seibyl J, Jennings D, Tabamo R, Marek K. Neuroimaging trials of Parkinson's disease progression. J Neurol 2004;251(Suppl 7):vII9–13.
   PubMedGoogle Scholar
• Gerlach M, Maetzler W, Broich K, et al. Biomarker candidates of neurodegeneration in Parkinson's disease for the evaluation of disease-modifying therapeutics. J Neural Transm 2012;119:39–52.
   PubMed Web of Science ®Google Scholar